View all newsletters
Receive our newsletter – data, insights and analysis delivered to you

Non-Alcoholic Steatohepatitis (NASH) accounts for 6.3% share of global Gastrointestinal clinical trial activity in 2020

By Carmen

Non-Alcoholic Steatohepatitis (NASH) accounted for a 6.3% share of the global clinical trials within the Gastrointestinal therapy area in 2020, registering an increase of 3.0% when compared with the last ten-year average of 3.3% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials for NASH

Industry sponsored trials held an 80.5% share of all the clinical trials for NASH indication in 2020, registering an increase of 32.0% when compared with the ten-year average of 48.5%. Non-industry sponsored trials accounted for a 19.5% share in 2020, marking a decrease of 32.0% over the ten-year average of 51.5%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored NASH trials

North America was the top region for industry sponsored NASH trials, accounting for a 53.4% share in 2020, when compared with the five-year average of 69.4% and ten-year average of 53.2%.

Asia-Pacific was at the second position with a 44.8% share in 2020, over the five-year average of 31.9% and ten-year average of 28.5%, followed by Europe with a 22.4% share in 2020, as against five-year and ten-year averages of 33.5% and 42.4% respectively.

Middle East and Africa stood fourth with an 8.6% share in 2020, compared with the five-year average of 11.2% and ten-year average of 13.6%, followed by South and Central America with a 6.9% share in 2020, over five-year and ten-year averages of 6.6% and 3.3% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

The US was the top country for industry sponsored NASH trials, accounting for a 51.7% share in 2020, as against the five-year average of 67.2% and ten-year average of 52.1%.

China held a 19.0% share in 2020, over the five-year average of 4.8% and ten-year average of 2.4%, followed by Australia with a 17.2% share in 2020, compared with the five-year and ten-year averages of 15.6% and 11.9% respectively.

Canada held a 12.1% share in 2020, as against the five-year average of 14.5% and ten-year average of 11.2%.

Japan held a 12.1% share in 2020, over the five-year and ten-year averages of 7.4% and 5.7% respectively.

Top regions of non-industry sponsored NASH trials

Asia-Pacific was the top region for non-industry sponsored NASH trials, accounting for a 52.9% share in 2020 when compared with the five-year average of 39.4% and ten-year average of 36.0%.

Middle East and Africa was at the second position with a 17.6% share in 2020, over the five-year and ten-year averages of 26.3% and 25.9% respectively, followed by North America with a 17.6% share in 2020, as against the five-year average of 23.4% and ten-year average of 19.7%.

Europe stood at the fourth position with an 11.8% share in 2020, compared with the five-year average of 10.9% and ten-year average of 18.4%, followed by South and Central America with a 0.0% share in 2020, over the five-year and ten-year averages of 1.1% and 0.5% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for non-industry sponsored NASH trials, accounting for a 23.5% share in 2020, as against the five-year average of 16.4% and ten-year average of 11.4%.

Iran held a 17.6% share in 2020, over the five-year average of 21.2% and ten-year average of 20.4%, followed by South Korea with a 17.6% share, compared with the five-year and ten-year averages of 2.1% and 1.0% respectively.

The US held a 17.6% share in 2020, as against the five-year average of 18.6% and ten-year average of 15.3%.

India held a 5.9% share in 2020, over the five-year average of 4.5% and ten-year average of 5.0%.

Phase I trials lead industry sponsored clinical trials for NASH in 2020

Phase I trials held a 57.1% share of industry sponsored clinical trials for NASH in 2020, over the five-year average of 48.2% and ten-year average of 44.1%.

Phase II trials held a 37.1% share in 2020, as against the five-year average of 45.6% and ten-year average of 48.4%. Phase III trials held a 5.7% share in 2020, compared with the five-year and ten-year averages of 5.2% and 6.9% respectively.

Phase IV trials held a 0.0% share in 2020, over the five-year average of 1.1% and ten-year average of 0.6%.

Phase II trials lead non-industry sponsored clinical trials for NASH in 2020

Phase II trials held a 58.8% share of non-industry sponsored clinical trials for NASH in 2020, over the five-year average of 61.2% and ten-year average of 66.8%.

Phase I trials held a 23.5% share in 2020, as against the five-year average of 12.7% and ten-year average of 7.1%. Phase III trials held an 11.8% share, compared with the five-year and ten-year averages of 14.1% and 15.1% respectively.

Phase IV trials held a 5.9% share in 2020, over the five-year average of 12.0% and ten-year average of 11.0%.

Methodology: The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena